{"public_id":"cl_ac9b31366f8e13f0501b64650e4735ba","status":"active","superseded_by_public_id":null,"corpus_id":251998037,"text":"Apatinib combined with homoharringtonine exerts a better antileukemia effect than apatinib alone in preclinical acute myeloid leukemia models.","confidence":0.93,"paper":{"corpus_id":251998037,"title":"Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia","url":"https://sah.borca.ai/papers/251998037"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_847a60003f984ca8fa9b14be6ce406d9","name":"antileukemia effect","description":"Activity that reduces or suppresses leukemia cell growth and survival.","types":["therapeutic effect"],"url":"https://sah.borca.ai/concepts/co_847a60003f984ca8fa9b14be6ce406d9"},{"public_id":"co_8540d3b167378285fe0b010ebcdadaed","name":"apatinib","description":"A small-molecule VEGFR-2 inhibitor evaluated here as an antileukemia agent.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_8540d3b167378285fe0b010ebcdadaed"},{"public_id":"co_c8a9a2c1c9a7ade3a48ac179d1d425cd","name":"apatinib combined with homoharringtonine","description":"The drug combination of apatinib and homoharringtonine tested for antileukemia activity.","types":["combination therapy"],"url":"https://sah.borca.ai/concepts/co_c8a9a2c1c9a7ade3a48ac179d1d425cd"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_ac9b31366f8e13f0501b64650e4735ba"}